Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 3/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466454 | 0.96 | CYP19A1 (0.48) | CYP19A1KCNA5NR3C1CYP11B2OXTR | |
| SCHEMBL4460426 | 0.94 | CYP19A1 (0.48) | CYP19A1KCNA5NR3C1CYP11B2OXTR | |
| SCHEMBL4472165 | 0.94 | CYP19A1 (0.45) | CYP19A1KCNA5NR3C1CYP11B2OXTR | |
| SCHEMBL4469601 | 0.89 | KCNA5 (0.42) | CYP19A1KCNA5PFKFB3 | |
| SCHEMBL4471213 | 0.87 | KCNA5 (0.42) | CYP19A1KCNA5CYP11B2OXTRAVPR1A | |
| SCHEMBL4464219 | 0.87 | CYP19A1 (0.41) | CYP19A1KCNA5NR3C1CYP11B2OXTR | |
| SCHEMBL4457212 | 0.86 | KCNA5 (0.42) | CYP19A1KCNA5OXTRAVPR1A | |
| SCHEMBL4461885 | 0.86 | CYP19A1 (0.59) | CYP19A1KCNA5CYP11B2CYP3A4 | |
| SCHEMBL4460589 | 0.85 | CYP19A1 (0.46) | CYP19A1KCNA5CYP11B2CYP3A4 | |
| SCHEMBL4461911 | 0.83 | CYP19A1 (0.46) | CYP19A1KCNA5CYP11B2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | claimed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20090030043-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| EP-1981507-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089679-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030043-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | CYP19A1 4359/4885KCNA5 11/4885NR3C1 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.